1-phenyl-2-(heterocyclyl-alkyl-amino)-ethanols

ABSTRACT

Compounds of the formula  wherein 
     Het is a heterocycle; 
     n is an integer from 1 to 4, inclusive, preferably 2 or 3; 
     R 1  is H or acyl; 
     R 2  is H, R 1  O, --NHSO 2  R 7 , --NHCOR 8 , --NHCONHR 8 , --NH--CH 2  --C 6  H 4  --R 9 , --CH 2  OH, --CH 2  SO 2  R 7 , --CONHR 8 , halogen or --CN; 
     R 3  is H, halogen, R 7  or --OR 7  ; or 
     R 2  and R 3 , together with each other, are ##STR1## N 4  is H, --CH 3  or --C 2  H 5  ; R 5  and R 6  are each H or --CH 3  ; 
     R 7  is C 1  -C 4  alkyl; 
     R 8  is H or C 1  -C 4  alkyl; and 
     R 9  is H, C 1  -C 4  alkyl or C 1  -C 4  alkoxy optionally interrupted by oxygen; 
     and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as the salts are useful as bronchospasmolytics, spasmolytics, muscle-relaxants, antiallergics and hypotensives.

This is a division of copending application Ser. No. 285,713, filed July 22, 1981, now U.S. Pat. No. 4,378,361; which, in turn, is a continuation of application Ser. No. 156,928, filed June 6, 1980, now abandoned; which, in turn, is a continuation of application Ser. No. 60,389, filed July 25, 1979, now abandoned.

This invention relates to novel heterocyclic compounds and salts thereof, to various methods of preparing these compounds, to pharmaceutical compositions containing them as active ingredients, and to methods of using them as broncholytics, uterus relaxants, antiallergics and hypotensives.

More particularly, the present invention relates to a novel class of heterocyclic compounds represented by the formula ##STR2## n is an integer from 1 to 4, inclusive, preferably 2 or 3, R₁ is H or acyl,

R₂ is H, R₁ O, --NHSO₂ R₇, --NHCOR₈, --NHCONHR₈, --NH--CH₂ --C₆ H₄ --R₉, --CH₂ OH, --CH₂ SO₂ R₇, --CONHR₈, halogen or --CN,

R₃ is H, halogen, R₇ or --OR₇,

R₂ and R₃, together with each other are ##STR3## R₄ is H, --CH₃ or --C₂ H₅, R₅ and R₆ are each H or --CH₃,

R₇ is C₁ -C₄ alkyl,

R₈ is H or C₁ -C₄ alkyl,

R₉ is H, C₁ -C₄ alkyl or C₁ -C₄ alkoxy optionally interrupted by oxygen,

R₁₀ is H, C₁ -C₄ alkyl, phenyl or pyridyl

R₁₁ and R₁₂ are each H, CH₃, Cl or OCH₃, or together methylenedioxy,

X is ##STR4## or N, and Z is --CH₂ or --CO;

in the form of racemates, enantiomers, diastereoisomeric antipode pairs, as well as non-toxic, pharmacologically acceptable acid addition salts thereof.

A preferred sub-genus thereunder is constituted by compounds of the formula I

wherein

R₁ is H,

R₂ is H, --OH, --NHSO₂ CH₃, --NHCOR₈, --NHCONHR₈, --NH--CH₂ --C₆ H₄ --R₉, --CH₂ OH, CH₂ SO₂ CH₃, --CONHR₈, Cl or F,

R₃ is H, Cl, --CH₃ or --OCH₃,

R₂ and R₃, together with each other are, ##STR5## R₄ is H, R₅, R₆, R₈ and R₁₀, which may be the same or different, are each H or --CH₃,

R₉ is H or 4--OCH₃,

Het is ##STR6## X is --CH═ or --N═, and n is an integer from 1 to 4, inclusive, preferably 2 or 3.

The compounds embraced by formula I may be prepared by the following methods:

METHOD A

By reducing an amino-ketone of the formula ##STR7## wherein R₁ through R₆, Het and n have the above-mentioned meanings, and wherein the central nitrogen atom and/or phenolic OH groups present, if any, may be protected by protective groups, separable by hydrogenation, in a suitable solvent with hydrogen and a hydrogenation catalyst or with hydrides have a reducing action, and protective groups still present are optionally removed after the reduction by hydrogenation.

METHOD B

For the preparation of those compounds of the formula I wherein R₄ is H, by reacting an amine of the formula ##STR8## wherein R₅, R₆, Het and n have the above-mentioned meanings, under the conditions of reductive amination with a phenyl-glyoxal of the formula ##STR9## wherein R₁, R₂ and R₃ have the above-mentioned meanings, and in which phenolic OH groups present, if any, may be protected by protective groups separable by hydrogenation, optionally in the form of a hemi-acetal, and optionally separating protective groups present by hydrogenation.

METHOD C

By removing the protective group or groups from a compound of the formula ##STR10## wherein R₃ to R₆, n and Het have the above-mentioned meanings and R' is H or a protective group separable by hydrogenation, R₁ ' is R₁ or a protective group separable by hydrogenation, R₂ ' is R₂, but in the definition thereof of R₁ is to be replaced by R₁ ', and wherein at least one of the radicals R₁ ' and R₂ ' is a protective group to be removed.

The end products obtained by methods A, B and C may, if desired, be separated into their enantiomers, optionally also into their diastereoisomeric antipode pairs, if desired, bases obtained may be converted into acid addition salts, and acid addition salts obtained may be converted into the free bases or into salts with other acids.

In method A, solvents which are sufficiently inert under the reaction conditions, for example alcohols such as methanol or ethanol, and conventional hydrogenation catalysts, for example palladium, platinum or Raney nickel are used. Hydrides which may be used as reducing agents are sodium borohydride and other complex hydrides, or diborane. The reaction temperature lies between about 0° C. and the boiling point of the reaction mixture. If the central amino group (contained in the side chain) or the substituents R₁ O and/or R₂ in the starting starting material have a protective group separable by hydrogenation, for example an optionally substituted benzyl group, attached thereto, this protective group is removed during, or, if necessary, after the reduction of the --CO-group.

The starting materials of the formula II are obtained, for example, by reaction of amines of the formula III with bromo-ketones of the formula IV in solvents, such as acetonitrile or ethyl acetate, in the presence of an acid-binding agent, such as sodium carbonate, or an excess of the amine: ##STR11## wherein R₁ ' is R₁ or a radical separable by hydrogenation, such as benzyl, R' is H or a radical separable by hydrogenation, such as benzyl, and the remaining substituents are as defined above.

In method B it is possible to use compound VI also in the form of a hemi-acetal, that is, in the form of a compound of the formula ##STR12## wherein R₁, R₂ and R₃ have the above-mentioned meanings, and alkyl represents an optionally substituted, preferably C₁ -C₆ alkyl radical.

The Schiff's bases of the formula VIII possibly occurring as intermediate compounds ##STR13## wherein the individual substituents are as defined above, may also be isolated and then subjected to reduction.

Complex hydrides, preferably sodium borohydride or hydrogen in the presence of hydrogenation catalysts, such as platinum, palladium or Raney nickel, are used as reducing agents. If R₁ O and/or R₂ are phenolic OH groups which are protected by a group separable by hydrogenation, such as benzyl, these groups are, if necessary, removed in the conventional way after reduction.

The amines of the formula are accessible, for example, by alkylating a heterocycle Het-H on the amino group with a compound of the formula ##STR14## wherein R₅ and R₆ have the meanings previously defined,

X is chlorine, bromine, methylsulfonic or tolylsulfonic acid radical, and

B is a functional group, such as NO₂, dibenzylamino or benzalamino, which may be converted into the amino group by catalytic hydrogenation or hydrolysis, in the presence of sodium hydride in solvents such as hexamethyl phosphoric acid triamide, and by converting thereafter the functional radical B into the amino group.

The phenyl glyoxals of the formula VI or the corresponding hemi-acetals of the formula VII may be obtained, for example, by oxidation of an acetophenone of the formula ##STR15## wherein R₁, R₂ and R₃ are as defined above, with selenium dioxide in aqueous dioxane and crystallization from water or alcohols.

In method C separation of the protective groups is effected with hydrogen and hydrogenation catalysts, such as palladium, platinum or Raney nickel, at temperatures between 0° C. and the boiling point of the reaction mixture. Lower alkanols, primarily methanol, serve preferably as solvents.

The starting materials of the formula XI may be prepared according to method A or B. Another possibility consists of converting precursors of R₂ ' in formula XI into R₂ ' compounds of the formula ##STR16## in which n, Het, R', R₁ ' and R₃ to R₆ have the above-mentioned meanings and R₂ " is a precursor of NH--CONH--R₈, NHCOR₈, NHSO₂ R or NH--CH₂ --C₆ H₄ --R₉ (e.g. NH₂), or of CH₂ OH or CONHR₈ (e.g. COOC₂ H₅), by conventional methods.

Thus, from compounds of the formula XII where R₂ " is NH₂, compounds of the formula XI wherein R₂ ' is NHCONH₂ may be obtained with potassium cyanate, or the compounds of the formula XI where R₂ ' is NH--COR₈ may be obtained with compounds of the formula (R₈ CO)₂ O. Compounds of the formula XII where R₂ " is COOC₂ H₅ yield by reduction with lithium aluminum hydride compounds of the formula XI where R₂ ' is CH₂ OH, and by reaction with amines of the formula H₂ NR₈ compounds of the formula XI where R₂ ' is CONHR₈ may be obtained.

The following examples illustrate the present invention and will enable others skilled in the art to understand it more completely. It should be understood, however, that the invention is not limited solely to the particular examples given below.

The compounds embraced by formula I are organic bases and therefore form acid addition salts with inorganic or organic acids. Examples of non-toxic, pharmacologically acceptable acid addition salts are those formed with hydrochloric acid, cyclamic acid, maleic acid, sulfuric acid, formic acid, succinic acid, methanesulfonic acid, cyclohexanesulfamic acid, fumaric acid, benzoic acid or the like.

EXAMPLE 1 1-(4-Hydroxy-phenyl)-2-[3-(1-benzimidazolyl)-propyl-amino]-ethanol and its dihydrochloride by method A

30.5 gm of 2-bromo-p-benzyloxyacetophenone and 35 gm of 1-aminopropyl-benzimidazole were stirred for 1 hour at 30°-40° C. in 150 ml of acetonitrile. After separation of the hydrobromide, the mother liquor was acidified with 12 gm of maleic acid, and the precipitated α-[3-(1-benzimidazolyl)-propylamino]-4-benzyloxyacetophenone maleate (m.p. 145°-148° C.) was collected by suction of filtiation. Aqueous ammonia was used to prepare the base, which was reduced in 200 ml of alcohol with sodium borohydride to form 1-(4-benzyloxyphenyl)-2-[3-(1-benzimidazolyl)-propylamino]-ethanol (m.p. 83°-85° C.).

Catalytic hydrogenation of 7 gm of this compound in 100 ml of methanol with 1 gm of palladium charcoal as the catalyst yielded 4.5 gm of 1-(4-hydroxyphenyl)-2-[3-(1-benzimidazolyl)-propylamino]-ethanol (m.p. 146°-148° C., 83% of theory), whose dihydrochloride of the formula ##STR17## had a melting point of 184°-185° C.

EXAMPLE 2 1-[3-(3-Carbamoyl-4,β-dihydroxy-phenethylamino)-propyl]-1-H-benzotriazole and its cyclamate by method A

A mixture of 17.5 gm of 2-benzyloxy-5-bromoacetyl salicylamide, 17.6 gm of 1-(3-aminopropyl)-1H-benzotriazole, 6 gm of sodium carbonate and 150 ml of ethyl acetate was refluxed for 1.5 hours. After separation of the inorganic constituents, the mother liquor was evaporated, the residue was dissolved in a 100 ml of acetonitrile, and the solution was acidified with 5 gm of oxalic acid. The precipitated 1-[3-(3-carbamoyl-4-benzyloxy-β-oxophenethylamino)-propyl]-1-H-benzotriazole oxalate was collected by suction of filtration converted with aqueous ammonia into the base (m.p. 186°-188° C.) and reduced in 100 ml of ethanol with sodium borohydride to form 1-[3-(3-carbamoyl-4-benzyloxy-β-hydroxyphenethylamino)-propyl]-1-H-benzotriazole.

Hydrogenation of 6 gm of this compound in 100 ml of methanol at a pressure of 6 bars and 40° C. in the presence of palladium charcoal yielded 3 gm of 1-[3-(3-carbamoyl-4,β-dihydroxy-phenethylamino)-propyl]-1-H-benzotriazole (m.p. 154°-155° C.), 77.5% of theory) whose cyclamate of the formula ##STR18## had a melting point of 165° C.

EXAMPLE 3 1-[3-Carbamoyl-4-β-dihydroxy-phenethylamino)-propyl]-3-methyl-quinazoline-2,4-dione dihydrochloride by method A

A mixture of 12.9 gm of 5-bromoacetyl salicylamide, 15.45 gm of 1-(3-benzylaminopropyl)-3-methyl-quinazoline-2,4-dione, 6 gm of sodium carbonate and 300 ml of acetonitrile was refluxed for 1.5 hours. After suction-filtering off the inorganic constituents, the mother liquor was evaporated, the residue was dissolved in 500 ml of methanol, and the solution was hydrogenated, after addition of 12 ml of benzyl chloride, at 6 bars and 60° C. with palladium charcoal as the catalyst. After 2 mols of hydrogen had been taken up, the hydrogenation was complete, and the resulting 1-[3-(3-carbamoyl-β-oxo-4-hydroxyphenethylamino)-phenyl]-3-methyl-quinazoline-2,4-dione hydrochloride (m.p.=253° C. with decomposition) was isolated.

Catalytic hydrogenation of 13 gm of this compound in 250 ml of a methanol/water mixture 1:1 at 6 bars pressure and 50° C. with palladium as the catalyst yielded 8 gm of 1-[3-(3-carbamoyl-4-β-dihydroxy-phenethylamino)-propyl]-3-methyl-quinazolin-2,4-dion hydrochloride of the formula ##STR19## which had a melting point of 220°-221° C. The yield was 61.5% of theory.

Using procedures analogous to those described in Examples 1 to 3, the following compounds of the formula I was also prepared:

                                      TABLE I                                      __________________________________________________________________________                                                            Melting point           Formula                                 Yield (%)                                                                            Salt with                                                                               in                      __________________________________________________________________________                                                            °C.               ##STR20##                              88    2 × maleic acid                                                                   178-180                  ##STR21##                              61    Sulphuric acid ×  2                                                      H.sub.2 O                                                                               199-202                  ##STR22##                              65    Sulphuric acid ×  0.5                                                    H.sub.2 O                                                                               174-176 163                                                                    (Base)                   ##STR23##                              80    Formic acid                                                                             158-160                  ##STR24##                              60    1.5 × succinic                                                                    154-156                  ##STR25##                              83    2 × maleic acid                                                                   137-140                  ##STR26##                              60    Methanesulphonic acid                                                                   178-180                  ##STR27##                              80    Formic acid                                                                             163-166                  ##STR28##                              65    Cyclohexane sulphaminic                                                        acid     174-176                 __________________________________________________________________________

EXAMPLE 4 1-(2,5-Dichloro-4-hydroxy-phenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol dihydrochloride by method B

A mixture of 9.3 gm of 2,5-dichloro-4-hydroxyphenyl-glyoxal hydrate, 7.25 gm of 1-(3-amino-3-methylbutyl)-benzimidazole and 100 ml of alcohol was stirred for 3 hours at 40°-45° C. The resulting solution was subsequently cooled, admixed in portions with 8 gm of sodium borohydride, and the mixture was stirred for 3 hours at room temperature. After the addition of 100 ml of methanol for decomposition of the sodium borohydride, the mixture was allowed to stand for 10 hours, the solvent was distilled off under reduced pressure, the residue was dissolved in 200 ml of water, and the solution was acidified with concentrated hydrochloric acid. 9.5 gm of 1-(2,5-dichloro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol dihydrochloride×1H₂ O, m.p. 180°-183° C., of the formula ##STR29## were obtained. The yield was 50.4% of theory.

EXAMPLE 5 2'-Hydroxy-5'-[1-hydroxy-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethyl]-methanesulfonanilide and its formate by method B

A mixture of 14.4 gm of 2'-benzyloxy-5'-(1-oxo-2-hydroxy-2-ethoxy-ethyl)-methanesulfonanilide, 7 gm of 1-(3-amino-3-methylbutyl)-benzimidazole and 150 ml of alcohol was heated for 3 hours at 50° C. and then admixed in portions with 9.2 gm of sodium borohydride. The resulting solution is kept for 12 hours at room temperature, the alcohol is then removed under reduced pressure on a Rotavapor, and the residue is dissolved with 200 ml of water and 500 ml of ethyl acetate. After decomposition of the sodium borohydride by stirring with concentrated hydrochloric acid and ice cooling, the mixture was made alkaline with aqueous ammonia, and the ethyl acetate phase was separated, dried with sodium sulfate and evaporated on a Rotavapor. The residue was dissolved in 200 ml of alcohol, the solution was acidified with 6.3 gm of oxalic acid, and the precipitated 2'-benzyloxy-5'-[1-hydroxy-2-[4-(1-benzimiazolyl)-2-methyl-2-butylamino]-ethyl]-methane sulfonanilide dioxalate (m.p. 185°-187° C.) is extracted. The base (m.p. 65°-70° C.) was liberated from this compound with aqueous ammonia. Catalytic hydrogenation of this compound (m.p. 65°-70° C.) in 250 ml of methanol under standard conditions with palladium charcoal as a catalyst yielded 8 gm of 2'-hydrox-5'-[1-hydroxy-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethyl]-methanesulfonanilide (m.p. 170°-173° C.; 81% of theory) whose formates of the formula ##STR30## had a melting point of 161°-164° C.

EXAMPLE 6 1-(2-Fluoro-4-hydroxy-phenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol and its formate by method B

A solution of 15.2 gm of 1-(2-fluoro-4-benzyloxyphenyl)-1-oxo-2-hydroxy-2-ethoxy-ethane in 200 ml of alcohol was admixed with 8.2 gm of 1-(3-amino-3-methylbutyl)-benzimidazole, and the mixture was stirred for 3 hours at 50° C. The resulting solution was subsequently cooled, admixed with 4 gm of sodium borohydride and stirred for 6 hours at room temperature. The mixture was then worked up as described in Example 3. The residue was dissolved in 200 ml of alcohol, the solution was acidified with 7.2 gm of oxalic acid, and the precipitated 1-(2-fluoro-4-benzyloxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol dioxalate (m.p. 184°-188° C.) was suction filtered off. The base (m.p. 85°-88° C.) was liberated from the dioxalate with aqueous ammonia.

Catalytic hydrogenation of this compound in 250 ml of methanol at 6 bars pressure with palladium charcoal as the catalyst at about 30° C. yielded 1-(2-fluoro-4-hydroxyphenyl)2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol, m.p. 151°-153° C., whose formate of the formula ##STR31## had a melting point of 157°-159° C.

By addition of the calculated quantity of methanesulfonic acid to the solution of the base in ethanol and the methanesulfonate, m.p. 178°-179° C. was obtained. The hydrochloride was prepared correspondingly, m.p. 205° C. The dihydrochloride tetrahydrate, m.p. 177° C., was obtained from the base in aqueous acetonitrile was the calculated quantity of concentrated hydrochloric acid. The sulfhate hydrate, m.p. 207°-208° C. was obtained analogously in aqueous ethanol.

Using procedures analogous to those described in Examples 4 to 6, the following compounds of the formula I were also prepared.

                                      TABLE II                                     __________________________________________________________________________                                              Yield                                 Formula                                  (%) Salt with                                                                               Melting point                                                                  °C.               __________________________________________________________________________      ##STR32##                               79.5                                                                               Formic acid                                                                             128                       ##STR33##                               85  Methanesulphonic acid                                                                   178-180 123 Base          ##STR34##                               54.5                                                                               Cyclohexane- sulphaminic                                                       acid     177-179 171 Base          ##STR35##                               79  2 × formic acid                                                          × 1H.sub.2 O                                                                      174-176 188-190                                                                Base                      ##STR36##                               83  Formic acid                                                                             163-166 193-196                                                                Base                      ##STR37##                               93  0.5 succinic                                                                            187-189 168-172                                                                Base                      ##STR38##                               85  Sulphuric acid ×                                                         1H.sub.2 O                                                                              173-175 174-176                                                                Base                      ##STR39##                               93  Maleic acid                                                                             190-193 181-183                                                                Base                      ##STR40##                               50  Cyclohexane- sulphaminic                                                       acid     162-164                   ##STR41##                               58  Sulphuric acid                                                                          224-226 decomp.           ##STR42##                               48.5                                                                               hydrochloric acid                                                                       208-210 decomp.           ##STR43##                               69  hydrochloric acid                                                                       208-210                   ##STR44##                               86  Formic acid                                                                             158-160 129-132                                                                Base                      ##STR45##                               92  Hydrochloric acid                                                                       203-204 decomp.                                                                165-167 Base              ##STR46##                               77.5                                                                               Cyclohexane- sulphaminic                                                       acid     177-180                   ##STR47##                               50  1.5 ×  succinic                                                                   154-156                   ##STR48##                               60  Formic acid × 1H.sub.2                                                   O        115-119                   ##STR49##                               87.5                                                                               2 × maleic acid                                                                   137-140 165-168                                                                Base                      ##STR50##                               62  2 × maleic acid                                                                   176-179 245 decomp.                                                            base                      ##STR51##                               82  Sulphuric acid                                                                          287 decomp. 218-220                                                            Base                      ##STR52##                               80  Maleic acid                                                                             185-186 175-178                                                                Base                      ##STR53##                               63  Maleic acid                                                                             173-174                   ##STR54##                               75  Maleic acid × 1/2Aceton                                                  nitrile  161-165 160-162                                                                Base                      ##STR55##                               72  Cyclohexane- sulphaminic                                                       acid     174-176 182-184                                                                Base                      ##STR56##                               81  Maleic acid                                                                             186-189 155-159           ##STR57##                               77.5                                                                               Fumaric acid                                                                            158- 160                  ##STR58##                               78  Formic acid × 1                                                                   175-178                   ##STR59##                               73.5                                                                               Maleic acid × 1/2ethano                                                  l        167-169                   ##STR60##                               77.5                                                                               2 × hydro- chloric                                                       acid     168-170 186-188                                                                Base                      ##STR61##                               82  Sulphuric acid                                                                          215-218 decomp.                                                                185-186 Base              ##STR62##                               77  2 × hydrochloric                                                                  185-186                   ##STR63##                               93  2 × hydrochloric                                                                  189-191 182-184                                                                Base                      ##STR64##                               92.5                                                                               Formic acid                                                                             180-182 125°                                                            decomp. Base              ##STR65##                               32           148-151 Base              ##STR66##                               74  Formic acid                                                                             170-172                   ##STR67##                               93  2 × hydro- chloric                                                       acid     165-168 163-165                                                                Base                      ##STR68##                               78.5                                                                               Formic acid                                                                             156-159 133-136                                                                Base                      ##STR69##                               87  2 × hydro- chloric                                                       acid     210- 212                  ##STR70##                               85  Formic acid                                                                             160-163 123-125          __________________________________________________________________________                                                           Base                

EXAMPLE 7 1-{3-[2-Hydroxy-2-(4-hydroxy-phenyl)-ethylamino]-propyl}-1,2,3,4-tetrahydro-4-quinazolone and its formate by method C

15.5 gm of 1-{-[2-hydroxy-2-(4-benzyloxy-phenyl)-benzylethylamino]-propyl}-1,2,3,4-tetrahydro-4-quinazolone (m.p. 119°-121° C.) were dissolved in 250 ml of methanol and debenzylated by hydrogenation at 60° C. and 6 bars pressure in the presence of palladium as the catalyst. After 2 mols of hydrogen had been taken up, the hydrogenation was complete, yielding of 8 gm of 1-{3-[2-hydroxy-2-(4-hydroxyphenyl)-ethylamino]-propyl}-1,2,3,4-tetrahydro-4-quinazolone, whose formate of the formula ##STR71## had a melting point of 174°-176° C. The yield was 61.5% of theory.

EXAMPLE 8 1-{2'-Hydroxy-5'-[1-hydroxy-2-[4-(1-imidazolyl)-2-methyl-2-butylamino]-ethyl]-phenyl}-urea and its sulfate by method C

A mixture of 15 gm of 2'-benzyloxy-5'-[1-hydroxy-2-[4-(1-imidazolyl)-2-methyl-2-butylamino]-ethyl]-acetanilide (m.p. of the dioxalate 160°-163° C.), 18.5 gm of KOH, 80 ml of alcohol and 15 ml of water was refluxed for 24 hours, and the resulting 1-(3-amino-4-benzyloxy-phenyl)-2-[4-(1-imidazolyl)-2-methyl-2-butylamino]-ethanol was isolated as the trioxalate (m.p. 95°-100° C.). Aqueous ammonia were used to liberate the base which was reacted with potassium cyanate to form 1-{2'-benzyloxy-5'-[1-hydroxy-2-[4-(1-imidazolyl)-2-methyl-2-butylamino]-ethyl]-phenyl}-urea (m.p. 142°-143° C.). Catalytic hydrogenation of 5.1 gm of this compound in 100 ml of methanol with palladium charcoal as the catalyst yielded 3.5 gm of 1-{2'-hydroxy-5'-[1-hydroxy-2-]-4-(1-imidazolyl)-2-methyl-2-butylamino]-ethyl]-phenyl}-urea, whose sulfate of the formula ##STR72## had a melting point of 243°-244° C. The yield was 70% of theory.

EXAMPLE 9 5-[1-Hydroxy-2-[4-(1-imidazolyl)-2-methyl-2-butylamino]-ethyl]-N-methyl-salicylamide sulfate by method C

8.5 gm of methyl 2'-benzyloxy-5'-[1-hydroxy-2-[4-(1-imidazolyl)-2-methyl-4-butylamino]-ethyl]-benzoate (m.p. of the dioxalate 156°-158° C.) were hydrogenated under standard conditions in 100 ml of methanol in the presence of palladium as the catalyst, and after 1 mol of hydrogen had been taken up the catalyst was filtered off, and 15 ml of monomethylamine were added to the filtrate. After 2 days of standing the solvent was distilled off, the residue was dissolved in 15 ml of alcohol and 15 ml of water, and the solution was acidified with 2 gm of concentrated sulfuric acid.

4.5 gm of 5-[1-hydroxy-2[4-(1-imidazolyl)-2-methyl-2-butylamino]-ethyl]-N-methyl-salicylamide sulfate of the formula ##STR73## having a melting point of 263°-265° C. (decomposition) were obtained. The yield was 52% of theory.

EXAMPLE 10 1-(3-Hydroxymethyl-4-hydroxy-phenyl)-2-[4-(1-imidazolyl)-2-methyl-2-butylamino]-ethanol and its benzoate by method C

13.5 gm of methyl 2'-benzyloxy-5'-[1-hydroxy-2-[4-(1-imidazolyl)-2-methyl-4-butylamino]-ethyl]-benzoate (m.p. of the dioxalate 156°-158° C.) were reduced in 200 ml of tetrahydrofuran with 6 gm of lithium aluminum hydride to form 1-(3-hydroxymethyl-4-benzyloxyphenyl)-2-[4-(1-imidazolyl)-2-methyl-2-butylamino]-ethanol, whose dioxalate melted at 144°-146° C. Aqueous ammonia was used to liberate the base from 10 gm of dioxalate, which was hydrogenated in 100 ml of methanol with palladium as the catalyst. 4.5 gm of 1-(3-hydroxymethyl-4-hydroxyphenyl)-2-[4-(1-imidazolyl)-2-methyl-2-butylamino]-ethanol (m.p. 135°-137° C.) were obtained; the benzoate thereof of the formula ##STR74## had a melting point of 150°-152° C. The yield was 83% of theory.

Using procedures analogous to those described in Example 7 to 10, the following compounds of the formula I were also prepared:

                                      TABLE III                                    __________________________________________________________________________     The following are prepared analogously                                         Formula                                 Yield %                                                                             Salt with                                                                               Melting point                                                                  °C.               __________________________________________________________________________      ##STR75##                              62.5 Sulphuric acid × 1                                                       water    183° C.                                                                 decomp.                   ##STR76##                              40   2 × fumaric                                                                       158-162                   ##STR77##                              60.8 Sulphuric acid                                                                          221-223                   ##STR78##                              52   Cyclohexane- sulfphuric                                                                 126-130                   ##STR79##                              48   Sulphuric acid                                                                          192-194 decomp.           ##STR80##                              80   2 × hydrochloric                                                                  157-159 175 Base          ##STR81##                              87.5 formic acid                                                                             167-169 144-146                                                                Base                      ##STR82##                              71   2 × formic                                                                        137-138                   ##STR83##                              87.5 Benzoic acid                                                                            165-166                   ##STR84##                              84   Formic acid                                                                             182-184                   ##STR85##                              79   Hydrochloric                                                                            223-225 183-186                                                                Base                      ##STR86##                              76   Methanesulphonic acid                                                                   193-194                   ##STR87##                              95   Methanesulphonic acid                                                                   186-188 127 Base          ##STR88##                              83   Hydrochloric                                                                            216-271                   ##STR89##                              45   Maleic acid                                                                             186-188                   ##STR90##                              52   Cyclohexane sulphaminic acid                                                   × 1 water                                                                         126-130                   ##STR91##                              83   Benzoic acid                                                                            150-152 137-137                                                                Base                      ##STR92##                              70   Sulphuric acid                                                                          235-236 142-145                                                                Base                      ##STR93##                              70   Sulphuric acid                                                                          243-244                   ##STR94##                              41   Benzoic acid × 1                                                                  130-133                   ##STR95##                              85   0.5 × fumaric acid                                                                192                       ##STR96##                              63   Maleic acid                                                                             155-157                   ##STR97##                              73.5 Sulphuric acid                                                                          187-188 decomp.           ##STR98##                              76   2 × hydrochloric acid                                                    × 2 water                                                                         166-168                   ##STR99##                              72   Formic acid                                                                             172-174                   ##STR100##                             60   2 × hydrochloric                                                                  200° C.                                                                 decomp.                  __________________________________________________________________________         PG,41

The compounds of the present invention, that is, those embraced by formula I above and their non-toxic, pharmaceutically acceptable acid addition salts, have useful pharmaceodynamic porperties. More particularly, they exhibit broncholytic, spasmolytic and anti-allergic activity, and may therefore be used for the treatment of bronchitis, asthma, urticaria, conjunctivitis, hay fever and cold ailments, also as relaxants of the muscles of the uterus, for example in prenatal complaints. Furthermore, the novel compounds are suitable for treatment of cardiovascular disturbances such as high blood pressure, diseases of the peripheral vessels and cardiac arrhythmia.

Mention must be made, finally, of their inhibiting activity on gastro-secretion and the primary anti-depressive activity on the central nervous system.

To be emphasised is the strong and long-lasting broncholytic activity which is associated with only small secondary effects on the heart and skeleton musculature.

The compounds of the formula I where R₂ is CONHR₈ exhibit hypotensive activity, while the remaining compounds exhibit the other activities specified.

The therapeutic dose is dependent on the compound used, on the nature of the condition, on the type of administration and also on the body weight, if local application is not adopted.

The following are effective daily doses for an adult: For broncholysis: orally 2-20 mg, by inhalation 0.1-1.5 mg, subcutaneously 0.2-1.5 mg. For uterine spasmolysis: orally 10-50 mg, as an infusion solution 0.1-1 mg in ampoules with 10 ml solution. For vasodilation: orally 20-100 mg, in the form of solutions for intramuscular injection 20-40 mg. As a hypotensive agent: orally 200-1800 mg.

For administration the conventional galenic preparations, for example capsules, tablets, coated tablets, solutions, suspensions, powders, creams, ointments, emulsions and sprays, are prepared from the compounds according to the invention. In pulmonary administration, powders with a particle diameter of 0.5 to 7 μm are preferably introduced into the bronchial region as an aerosol with breathing air, optionally also with additional propellent gases.

Parenteral application is effected preferably in the form of sterile isotonic aqueous solutions, while primarily lotions, creams, ointments, emulsions and sprays serve for local application.

The favorable levels of activity of the compounds according to the invention are demonstrated by the following data.

1. Bronchospasmolysis

The activity was tested on guinea pigs under urethane anaesthesia. Body plethysmography was used to determine the influence on acetylcholine bronchospasm after intravenous and oral application. Furhtermore, the heart frequency was monitored.

    ______________________________________                                                 Broncholysis  Resorption                                                       ED.sub.50 μg/kg                                                                           ratio                                                    Compound  intravenous                                                                               oral     oral/intravenous                                 ______________________________________                                         Table III,                                                                               1.2        7.6      6.3                                              16th compound                                                                  Table II, 1.8        66       37                                               16th compound                                                                  Table III,                                                                               0.9        14       16                                               15th compound                                                                  Table II, 7.6        190      25                                               21st compound                                                                  Example 6 3.6        7        1.9                                              Table III,                                                                               0.09       5.4      60                                               24th compound                                                                  Salbutamol                                                                               9.2        1000     109                                              ______________________________________                                    

The compounds according to the invention show an outstanding relationship between intravenous and oral activity. The influence on heart rat is simultaneously small. Furthermore, the toxicity is so low that a considerable therapeutic spectrum is obtained; for example, for the compound according to Example 6 the LD₅₀ in mice is 29 mg/kg i.v. and 330 mg/kg p.o.

2. Uterine relaxation

Uterine relaxation was investigated on anesthetized rats. The intravenous ED₅₀ of uterine relaxation was determined in ug/kg (50% of the tested aniamls react) and the (undesirable) increase in heart rate at the ED₅₀ value was also determined. The comparison compound was fenoterol.

    ______________________________________                                                                Increase Increase                                                 Uterine re-  in heart in heart                                                 laxation     rate     rate                                                     ED.sub.50 (g/kg)                                                                            (beats   in comparison                                  Compound  i.v.         per min.)                                                                               with fenoterol                                 ______________________________________                                         Table III 0.82         19       1/2                                            10th compound                                                                  Table II, 0.76         18       1/2                                            11th compound                                                                  Table II, 0.44         23       2/3                                            15th compound                                                                  Table II, 0.5          18       1/2                                            32nd compound                                                                  Fenoterol 0.45         36       1                                              ______________________________________                                    

The compounds according to the invention thus bring about upon application of the ED₅₀ of uterine relaxation a considerably smaller increase of heart rate than the commercial product fenoterol.

The following illustrate a few pharmaceutical dosage unit compositions comprising a compound of the present invention as an active ingredient and represent the best modes contemplated of putting the invention into practical use.

    ______________________________________                                         Tablets                                                                        Composition of one tablet:                                                     ______________________________________                                         Active substance according to the invention                                                              20     mg                                            Colloidal silicic acid    10     mg                                            Lactose                   118    mg                                            Potato starch             60     mg                                            Polyvinyl pyrrolidone     6      mg                                            Sodium cellulose glycolate                                                                               4      mg                                            Magnesium stearate        2      mg                                                                      220    mg                                            ______________________________________                                    

    ______________________________________                                         Ampules                                                                        Composition of the solution per ampule:                                        ______________________________________                                         Active substance according to the invention                                                              10     mg                                            Sorbitol                  40     mg                                            Distilled water q.s. ad   10     ml                                            ______________________________________                                    

    ______________________________________                                         Suppositories                                                                  Composition per suppository:                                                   ______________________________________                                         Active substance according to the invention                                                              100    mg                                            Suppository base (cocoa butter)                                                                          1600   mg                                                                      1700   mg                                            ______________________________________                                    

Inhalation powder

0.5 mg of active substance according to the invention and 19.5 mg of lactose with a particle diameter between 0.5 and 7 μm are used for each hard gelatine capsule.

The active substances according to the invention may also be combined with known active substances; for broncholytic application, for example with theophyllines, parasympatholytics (e.g. ipratropium bromide), secretolytics (e.g. bromohexine), musculotropic spasmolytics (e.g. papaverine), corticosteroids, anti-allergic agents. With uterine relaxants among others combinations with corticosteroids are possible.

While the present invention has been illustrated with the aid of certain specific embodiments thereof, it will be readily apparent to others skilled in the art that the invention is not limited to these particular embodiments, and that various changes and modifications may be made without departing from the spirit of the invention or the scope of the appended claims. 

We claim:
 1. A racemate, enantiomer or diastereoisomeric antipode pair of a compound of the formula ##STR101## wherein n is an integer from 1 to 4, inclusive,R₂ is H, --OH, --NHSO₂ R₇, --NHCOR₈, --NHCONHR₈, --NH--CH₂ --C₆ H₄ --R₉, --CH₂ OH, --CH₂ SO₂ R₇, --CONHR₈, halogen or --CN, R₃ is H, halogen, R₇ or --OR₇, R₄ is H, --CH₃ or --C₂ H₅, R₅ and R₆ are each H or --CH₃, R₇ is C₁ -C₄ alkyl, R₈ is H or C₁ -C₄ alkyl, R₉ is H, C₁ -C₄ alkyl or C₁ -C₄ alkoxy, optionally interrupted by oxygen, R₁₁ and R₁₂ are each H, --CH₃, Cl or --OCH₃, or together methylenedioxy, and R₁₀ is H, C₁ -C₄ alkyl, phenyl or pyridyl,or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 2. A compound of claim 1,wherein R₂ is H, --OH, --NHSO₂ CH₃, --NHCOR₈, --NHCONHR₈, --NH--CH₂ --C₆ H₄ --R₉, --CH₂ OH, --CH₂ SO₂ CH₃, --CONHR₈, Cl or F, R₃ is H, Cl, --CH₃ or --OCH₃, R₄ is H, R₅, R₆ and R₈ are each H or --CH₃, R₉ is H or 4-OCH₃, R₁₀, R₁₁ and R₁₂ are H, and n is an integer from 1 to 4, inclusive,or a non-toxic, pharmacologically acceptable acid addition salt thereof.
 3. A compound of claim 1, wherein n is 2 or
 3. 4. A compound of claim 2, wherein n is 2 or
 3. 5. A broncholytic, uterus-relaxing or antiallergic pharmaceutical dosage unit composition consisting essentially of an inert pharmaceutical carrier and an effective broncholytic, uterus-relaxing or antiallergic amount of a compound of claim 1 wherein R₂ is other than --CONHR₈.
 6. A hypotensive pharmaceutical dosage unit composition consisting essentially of an inert pharmaceutical carrier and an effective hypotensive amount of a compound of claim 1 where R₂ is --CONHR₈.
 7. A compound of claim 1 which is 1-(2-fluoro-4-hydroxy-phenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol.
 8. A composition of claim 5 where said compound is 1-(2-fluoro-4-hydroxy-phenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]-ethanol. 